- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07663305
Evaluation of a Mobile Menopause Application (EMMA)
This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Hanover, Tyskland
- Rekrytering
- Medicoles
-
Huvudutredare:
- Elisabeth Siegmund-Schultze, Dr. med.
-
Kontakt:
- Elisabeth Siegmund-Schultze, Dr. med.
- E-post: studienleitung@wechseljahr-studie.de
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Legal capacity
- Ability to provide informed consent
- Residency in Germany
- Female gender
- Age ≥18 years
- Medically confirmed menopausal or other perimenopausal disorder (N95.1)
- Ownership of a smartphone and ability to use it
- Internet access for app usage and questionnaire completion
- Email address for registration
- Willingness to complete questionnaires online
- Motivation for regular app usage
- Sufficient proficiency in the German language
- MRS II ≥ 9
- Absence of exclusion criteria
Exclusion Criteria:
- Pregnancy or breastfeeding during the study period
- Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period
- Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period
- Start of psychotherapy within eight weeks prior to study start and/or planned during the study period
- Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period
- Surgery performed within eight weeks prior to study start and/or planned during the study period
- Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
- Current participation in other clinical studies
- Failure to meet the inclusion criteria
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Control Group
The control group has access to care-as-usual only. |
|
|
Experimentell: Intervention Group
The intervention group has access to the menopause app and its functions in addition to care-as-usual. |
The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Menopause-specific quality of life
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Menopause-specific symptom severity
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause Rating Scale (MRS II) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Daily interference due to hot flashes
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-specific impairment in daily activities
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Patient activation
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Patient Activation Measure 13 (PAM-13) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Menopause-specific quality of life
Tidsram: Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
|
Menopause-related absenteeism
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the absenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related presenteeism
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the presenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related work productivity loss
Tidsram: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the work productivity loss domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- RCT_EMMA
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .